Abstract
Boehringer Ingelheim has started up a $78 million biopharmaceutical plant at the Zhangjiang Hi-Tech Park in Shanghai. The facility, the company claims, is the only biopharmaceutical plant started up in China by a major international producer. Boehringer plans to use the plant to supply monoclonal antibodies and recombinant proteins to its customers in China. Separately, Boehringer announced that it will fund early drug discovery projects at Peking University. Several academic investigators will work closely with the German firm, Boehringer says.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
